Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with prolonged predicted survival even in patients with incomplete biochemical improvements

被引：1
|
作者：
Corpechot, Christophe [1 ,2 ]
Rousseau, Alexandra [3 ]
Lemoinne, Sara [1 ,2 ]
Farid, Gaouar [1 ]
Ben Belkacem, Karima [1 ]
Poupon, Raoul [1 ]
Chazouilleres, Olivier [1 ,2 ]
机构：
[1] St Antoine Hosp, AP HP, Reference Ctr Inflammatory Biliary Dis & Autoimmu, Paris, France
[2] Sorbonne Univ, INSERM, UMR S938, Paris, France
[3] St Antoine Hosp, AP HP, Clin Res Platform East Paris, Paris, France
来源：
JOURNAL OF HEPATOLOGY | 2019年 / 70卷 / 01期
关键词：
D O I：
10.1016/S0618-8278(19)30759-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-009
引用
收藏
页码：E386 / E387
页数：2
相关论文
共 40 条
  • [1] Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis - even in patients without biochemical improvements
    Harms, M.
    Van Buuren, H.
    Lammers, W. J.
    Corpechot, C.
    Thorburn, D.
    Invernizzi, P.
    Janssen, H.
    Battezzati, P. M.
    Nevens, F.
    Lindor, K.
    Floreani, A.
    Ponsioen, C.
    Mayo, M. J.
    Pares, A.
    Mason, A. L.
    Kowdley, K. V.
    Hirschfield, G.
    Hansen, B.
    Van der Meer, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S8 - S8
  • [2] Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add-on in primary biliary cholangitis with incomplete UDCA response
    Corpechot, Christophe
    Chazouilleres, Olivier
    Lemoinne, Sara
    Rousseau, Alexandra
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (02) : 236 - 238
  • [3] Bezafibrate add-on therapy improves liver transplantation-free survival in patients with primary biliary cholangitis: a Japanese nationwide cohort study
    Tanaka, Atsushi
    Hirohara, Junko
    Nakano, Toshinari
    Matsumoto, Kosuke
    Chazouilleres, Olivier
    Takikawa, Hajime
    Hansen, Bettina
    Carrat, Fabrice
    Corpechot, Christophe
    JOURNAL OF HEPATOLOGY, 2020, 73 : S1 - S1
  • [4] Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
    Hirschfield, G.
    Kupcinskas, L.
    Ott, P.
    Beuers, U.
    Bergquist, A. M.
    Farkkila, M.
    Manns, M. P.
    Pares, A.
    Spengler, U.
    Greinwald, R.
    Proels, M.
    Poupon, R.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S38 - S38
  • [5] Changes in serum bile acid levels associated with bezafibrate add-on therapy in patients with primary biliary cholangitis and inadequate biochemical response to ursodeoxycholic acid: results from the BEZURSO trial (NCT01654731)
    Corpechot, Christophe
    Chazouilleres, Olivier
    Humbert, Lydie
    Rousseau, Alexandra
    Le Gruyer, Antonia
    Habersetzer, Francois
    Mathurin, Philippe
    Goria, Odile
    Potier, Pascal
    Anne, Minello
    Silvain, Christine
    Abergel, Armando
    Debette-Gratien, Maryline
    Larrey, Dominique G.
    Roux, Olivier
    Bronowicki, Jean-Pierre
    Boursier, Jerome
    de Ledinghen, Victor
    Heurgue-Berlot, Alexandra
    Nguyen-Khac, Eric
    Zoulim, Fabien
    Ollivier-Hourmand, Isabelle
    Zarski, Jean-Pierre H.
    Nkontchou, Gisele
    Gaouar, Farid
    Simon, Tabassome
    Poupon, Raoul
    Rainteau, Dominique
    HEPATOLOGY, 2017, 66 : 168A - 168A
  • [6] Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with an improvement of fibrometer and fibrometer-VCTE, two high-accuracy non-invasive fibrosis tests extensively validated in frequent chronic liver diseases
    Corpechot, Christophe
    Rousseau, Alexandra
    Lemoinne, Sara
    Farid, Gaouar
    Ben Belkacem, Karima
    Poupon, Raoul
    Chazouilleres, Olivier
    Cales, Paul
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E387 - E387
  • [7] Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomena
    Li, Mengqi
    Chen, Sha
    Li, Shuxiang
    Lv, Tingting
    Li, Buer
    Shan, Shan
    Li, Min
    Zeng, Na
    Wang, Qianyi
    Kong, Yuanyuan
    Ma, Hong
    Zhao, Xinyan
    Ou, Xiaojuan
    You, Hong
    Duan, Weijia
    Jia, Jidong
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [8] Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA
    Duan, Weijia
    Ou, Xiaojuan
    Wang, Xiaoming
    Wang, Yu
    Zhao, Xinyan
    Wang, Qianyi
    Wu, Xiaoning
    Zhang, Wei
    Ma, Hong
    You, Hong
    Jia, Jidong
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2018, 110 (09) : 557 - 563
  • [9] Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
    Yamaoka-Tojo, Minako
    Tojo, Taiki
    Kosugi, Rie
    Hatakeyama, Yuko
    Yoshida, Yuki
    Machida, Yoji
    Aoyama, Naoyoshi
    Masuda, Takashi
    Izumi, Tohru
    LIPIDS IN HEALTH AND DISEASE, 2009, 8
  • [10] Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
    Minako Yamaoka-Tojo
    Taiki Tojo
    Rie Kosugi
    Yuko Hatakeyama
    Yuki Yoshida
    Yoji Machida
    Naoyoshi Aoyama
    Takashi Masuda
    Tohru Izumi
    Lipids in Health and Disease, 8
1234